Oryan A
Department of Pathobiology, School of Veterinary Medicine, Shiraz University, Shiraz, Iran.
Iran J Vet Res. 2015 Winter;16(1):1-19.
Leishmaniasis is a neglected public health problem caused by the protozoan species belonging to the genus Leishmania affecting mostly the poor populations of developing countries. The causative organism is transmitted by female sandflies. Cutaneous, mucocutaneous, and visceral clinical manifestations are the most frequent forms of leishmaniasis. Chemotherapy still relies on the use of pentavalent antimonials, amphotericin B, paromomycin, miltefosin and liposomal amphotericin B. However, the application of these drugs is limited due to low efficacy, life-threatening side effects, high toxicity, induction of parasite resistance, length of treatment and high cost. Given the fact that antileishmanial vaccines may not become available in the near future, the search for better drugs should be continued. Natural products may offer an unlimited source of chemical diversity to identify new drug modules. New medicines should be less toxic or non-toxic, safe, more efficient, less expensive and readily available antileishmanial agents, especially for low-income populations. In the present review, special focus is on medicinal plants used against leishmanaiasis. The bioactive phytocompounds present in the plant derivatives including the crude extracts, essential oils, and other useful compounds can be a good source for discovering and producing new antileishmanial medicines.
利什曼病是一个被忽视的公共卫生问题,由属于利什曼原虫属的原生动物物种引起,主要影响发展中国家的贫困人口。致病生物体由雌性白蛉传播。皮肤型、黏膜皮肤型和内脏型临床表现是利什曼病最常见的形式。化疗仍然依赖于使用五价锑剂、两性霉素B、巴龙霉素、米替福新和脂质体两性霉素B。然而,由于疗效低、危及生命的副作用、高毒性、诱导寄生虫耐药性、治疗时间长和成本高,这些药物的应用受到限制。鉴于抗利什曼病疫苗在不久的将来可能无法获得,应继续寻找更好的药物。天然产物可能提供无限的化学多样性来源,以识别新的药物模块。新药应该是毒性较小或无毒、安全、更有效、成本更低且易于获得的抗利什曼病药物,特别是对于低收入人群。在本综述中,特别关注用于治疗利什曼病的药用植物。植物衍生物中存在的生物活性植物化合物,包括粗提物、精油和其他有用化合物,可能是发现和生产新的抗利什曼病药物的良好来源。
Iran J Vet Res. 2015
Mar Drugs. 2017-10-29
Pathog Glob Health. 2020-5-18
Parasitol Res. 2020-12
Parassitologia. 2004-6
Front Microbiol. 2012-8-6
BMC Complement Med Ther. 2025-7-16
Pharmaceuticals (Basel). 2024-12-24
Pharmaceuticals (Basel). 2023-9-28
Res Rep Trop Med. 2012-7-26
PLoS Negl Trop Dis. 2014-12-11
Exp Parasitol. 2014-8
Trop Parasitol. 2014-1